Cargando…

Passive Monoclonal and Polyclonal Antibody Therapies

Passive antibody therapies have a long history of use. In the 19th century, antibodies from xenographic sources of polyclonal antibodies were used to treat infections (diphtheria). They were used often as protection from infectious agents and toxins. Complications related to their use involved devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelletier, J. Peter R., Mukhtar, Faisal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153350/
http://dx.doi.org/10.1016/B978-0-323-67509-3.00016-0
_version_ 1783521635103408128
author Pelletier, J. Peter R.
Mukhtar, Faisal
author_facet Pelletier, J. Peter R.
Mukhtar, Faisal
author_sort Pelletier, J. Peter R.
collection PubMed
description Passive antibody therapies have a long history of use. In the 19th century, antibodies from xenographic sources of polyclonal antibodies were used to treat infections (diphtheria). They were used often as protection from infectious agents and toxins. Complications related to their use involved development of immune complexes and severe allergic reactions. As a result, human source plasma for polyclonal antibodies became the preferential source for antibodies. They are used to treat infection, remove toxins, prevent hemolytic disease of the newborn, modify inflammatory reactions, and control autoimmune diseases. Continued improvements in processing decreased the transfusion/infusion transmission of infections. In the late 20th century (∼1986), monoclonal antibodies were developed. The first monoclonal antibodies were of xenographic source and were wrought with problems of immunogenicity. These forms of antibodies did not gain favor until chimerization took pace in the mid-1990s and in 1998 two monoclonal antibodies were approved one to treat respiratory syncytial virus and the other for breast cancers. Further development of humanized and then fully human monoclonal antibodies has led to an evolution of therapies with these agents. Monoclonal antibodies are being researched or approved to treat a multitude of diseases to include oncologic, inflammatory, autoimmune, cardiovascular, respiratory, neurologic, allergic, benign hematologic, infections, orthopedic, coagulopathy, metabolic and to decrease morbidity of disease (diminution of pain), modify disease progression, and potentially anatomic development. In this chapter, we will review the history of use of these passive antibody therapies, their mechanism of action, pharmacologic-therapeutic classification, particular medical indication, adverse reactions, and potential future use of these medications.
format Online
Article
Text
id pubmed-7153350
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-71533502020-04-13 Passive Monoclonal and Polyclonal Antibody Therapies Pelletier, J. Peter R. Mukhtar, Faisal Immunologic Concepts in Transfusion Medicine Article Passive antibody therapies have a long history of use. In the 19th century, antibodies from xenographic sources of polyclonal antibodies were used to treat infections (diphtheria). They were used often as protection from infectious agents and toxins. Complications related to their use involved development of immune complexes and severe allergic reactions. As a result, human source plasma for polyclonal antibodies became the preferential source for antibodies. They are used to treat infection, remove toxins, prevent hemolytic disease of the newborn, modify inflammatory reactions, and control autoimmune diseases. Continued improvements in processing decreased the transfusion/infusion transmission of infections. In the late 20th century (∼1986), monoclonal antibodies were developed. The first monoclonal antibodies were of xenographic source and were wrought with problems of immunogenicity. These forms of antibodies did not gain favor until chimerization took pace in the mid-1990s and in 1998 two monoclonal antibodies were approved one to treat respiratory syncytial virus and the other for breast cancers. Further development of humanized and then fully human monoclonal antibodies has led to an evolution of therapies with these agents. Monoclonal antibodies are being researched or approved to treat a multitude of diseases to include oncologic, inflammatory, autoimmune, cardiovascular, respiratory, neurologic, allergic, benign hematologic, infections, orthopedic, coagulopathy, metabolic and to decrease morbidity of disease (diminution of pain), modify disease progression, and potentially anatomic development. In this chapter, we will review the history of use of these passive antibody therapies, their mechanism of action, pharmacologic-therapeutic classification, particular medical indication, adverse reactions, and potential future use of these medications. 2020 2019-11-22 /pmc/articles/PMC7153350/ http://dx.doi.org/10.1016/B978-0-323-67509-3.00016-0 Text en Copyright © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Pelletier, J. Peter R.
Mukhtar, Faisal
Passive Monoclonal and Polyclonal Antibody Therapies
title Passive Monoclonal and Polyclonal Antibody Therapies
title_full Passive Monoclonal and Polyclonal Antibody Therapies
title_fullStr Passive Monoclonal and Polyclonal Antibody Therapies
title_full_unstemmed Passive Monoclonal and Polyclonal Antibody Therapies
title_short Passive Monoclonal and Polyclonal Antibody Therapies
title_sort passive monoclonal and polyclonal antibody therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153350/
http://dx.doi.org/10.1016/B978-0-323-67509-3.00016-0
work_keys_str_mv AT pelletierjpeterr passivemonoclonalandpolyclonalantibodytherapies
AT mukhtarfaisal passivemonoclonalandpolyclonalantibodytherapies